Overview

Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects

Status:
Completed

Trial end date:
2015-04-01

Target enrollment:

Participant gender:

Summary

Primary objective: Comparison of independently assessed progression free survival (PFS) in subjects administered Bevacizumab + Temsirolimus vs. those administered Bevacizumab + Interferon-Alfa. Secondary objectives: safety, Investigator assessed PFS, objective response rate (independently assessed), and overall survival.

Phase:

Phase 3

Details

Lead Sponsor:

Pfizer

Treatments:

Bevacizumab
Everolimus
Interferon-alpha
Interferons
Sirolimus